Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF

Translational Oncology

Volumn 1, Issue 2, 2008, Pages 65-72

  Yamamoto, Nobuto ^a   Suyama, Hirofumi ^b   Yamamoto, Nobuyuki ^a  

^a Socrates Institute for Therapeutic Immunology   (United States)

^b Nagasaki Immunotherapy Research Group   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349470282     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.08106     Document Type: Article

References (49)

1. Klein LA (1968). Prostatic carcinoma. N Engl J Med 300, 824-833.
2. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, and Friedman MA (1985). A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3, 827-841.
3. Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Delaninian S, and Housset M (1996). Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 77, 1144-1148.
4. Raghavan D (1988). Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15, 371-389.
5. Tannock IF (1985). Is there evidence that chemotherapy is of benefit to patients with carcinoma of prostate? J Clin Oncol 3, 1013-1021.
6. Morton D, Eibler FR, Malmgren RA, and Wood WC (1970). Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158-164.
7. Zbar B and Tanaka T (1971). Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 172, 271-273.
8. Ngwenya BZ and Yamamoto N (1985). Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim Biophys Acta 839, 9-15.
9. Ngwenya BZ and Yamamoto N (1986). Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages. Cancer Immunol Immunother 21, 174-182.
10. Ngwenya BZ and Yamamoto N (1990). Contribution of lysophosphatidylcholine treated nonadherent cells to mechanism of macrophage activation. Proc Soc Exp Biol Med 193, 118-124.
11. Yamamoto N and Ngwenya BZ (1987). Activation of macrophages by lysophospholipids, and ether derivatives of neutral lipids and phospholipids. Cancer Res 47, 2008-2013.
12. Yamamoto N, Ngwenya BZ, and Pieringer PA (1987). Activation of macrophages by ether analogues of lysophospholipids. Cancer Immunol Immunother 25, 185-192.
13. Yamamoto N, St Claire DA, Homma S, and Ngwenya BZ (1988). Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res 48, 6044-6049.
14. Yamamoto N and Ueda M (2006). Treatment of cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF) rapidly eradicates cancerous cells. J Immunother 29, 677-678.
15. Yamamoto N and Ueda M (2004). Therapeutic efficacy of vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers. Immunology 2004, Bologna, Italy: Medmond Ltd, pp. 201-204.
16. Homma S and Yamamoto N (1990). Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin Exp Immunol 79, 307-313.
17. Yamamoto N, Homma S, and Millman I (1991). Identification of the serum factor required for in vitro activation of macrophages: role of vitamin D-binding protein (group-specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 147, 273-280.
18. Yamamoto N, Homma S, Haddad JG, and Kowalski MN (1991). Vitamin D3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells. Immunology 74, 420-424.
19. Homma S, Yamamoto M, and Yamamoto N (1993). Vitamin D binding protein (group-specific component, Gc) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol Cell Biol 71, 249-257.
20. Yamamoto N and Homma S (1991). Vitamin D3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal from lysophospatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88, 8539-8543.
21. 3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of β-galactosidase of B cells and sialidase of T cells. J Immunol 151, 2794-2802.
22. Naraparaju VR and Yamamoto N (1994). Roles of β-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages. Immunol Lett 43, 143-148.
23. Yamamoto N (1996). Structural definition of a potent macrophage activating factor derived from vitamin D3 binding protein with adjuvant activity for antibody production. Mol Immunol 33, 1157-1164.
24. Yamamoto N (1998). Vitamin D and the immune system. In Delves PJ and Roitt I (Eds). Encyclopedia of Immunology, 2nd ed, London, England: Academic Press Ltd, pp. 2494-2499.
25. Yamamoto N, Naraparaju VR, and Asbell SO (1996). Deglycosylation of serum vitamin D-binding protein and immunosuppression in cancer patients. Cancer Res 56, 2827-2831.
26. Yamamoto N, Naraparaju VR, and Urade M (1997). Prognostic utility of serum α-N -acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 57, 295-299.
27. Yamamoto N and Ueda M (2004). Eradication of HIV by treatment of HIVinfected/AIDS patients with vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF). Immunology 2004, Bologna, Italy: Medmond Ltd, pp. 197-200.
28. Yamamoto N, Naraparaju VR, and Srinivasula SM (1995). Structural modification of serum vitamin D3-binding protein and immunosuppression in HIVinfected patients. AIDS Res Hum Retroviruses 11, 1373-1378.
29. Yamamoto N (2006). Pathogenic significance of α-N -acetylgalactosaminidase found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 22, 262-271.
30. Yamamoto N and Urade M (2005). Pathogenic significance of α-N -acetylgalactosaminidase found in the hemagglutinin of influenza virus. Microbes Infect 7, 674-681.
31. Yamamoto N and Naraparaju VR (1998). Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Immunol Cell Biol 76, 237-244.
32. Koga Y, Naraparaju VR, and Yamamoto N (1999). Antitumor effects of vitamin D3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice. Proc Soc Exp Biol Med 220, 20-26.
33. Yamamoto N and Naraparaju VR (1997). Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res 57, 2187-2192.
34. Yamamoto N, Suyama H, Yamamoto N-Y, and Ushijima N (2008). Immunotherapy of metastatic breast cancer patients with vitamin D-binding proteinderived macrophage activating factor (GcMAF). Int J Cancer 122, 461-467.
35. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, and Livingston PO (1998). Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4, 293-302.
36. Yamamoto N, Suyama H, Nakazato H, Yamamoto N-Y, and Koga Y (2008). Immunotherapy of metastatic colorectal cancer with vitamin D-binding proteinderived macrophage-activating factor, GcMAF. Cancer Immunol Immunother 57, 1007-1016.
37. Murphy GP (1995). The Second Stanford Conference on international standardization of PSA assays. Cancer 75, 1-7.
38. Murphy GP, Barren RJ, Erickson SJ, Bowes BW, Wolfert RL, Bartsch G, Klocker H, Pointaner J, Reissigl A, McLeod DG, et al. (1996). Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer 74, 809-818.
39. Reddi AL, Sankaranarayanan K, Arulraj HS, Devaraj N, and Devaraj H (2000). Serum α-N -acetylgalactosaminidase is associated with diagnosis/prognosis of patients with squamous cell carcinoma of uterine cervix. Cancer Lett 158, 61-64.
40. Link RP, Perlman KL, Pierce EA, Schnoes HK, and DeLuca HF (1986). Purification of human serum vitamin D-binding protein by 25-hydroxyvitamn D3-Sepharose chromatography. Anal Biochem 157, 262-269.
41. Yamamoto N, Willett NP, and Lindsay DD (1994). Participation of serum proteins in the inflammation-primed activation of macrophages. Inflammation 18, 311-322.
42. Yamamoto N, Kumashiro R, Yamamoto M, Willett NP, and Lindsay ND (1993). Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D3-binding protein and albumin. Infect Immun 61, 5388-5391.
43. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
44. Mignatti P and Rifkin DB (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73, 161-195.
45. Osterling JE (1991). Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145, 907-923.
46. Kamoshida S and Tsutsumi Y (1990). Extra prostatic localization of prostate acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 21, 1108-1111.
47. Van Krieken TH (1993). Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol 17, 410-414.
48. Yu H, Giai M, Diamandis EP, Katsaros D, Southerland DJA, Levesque MA, Roagna R, Ponzone R, and Sismondi P (1995). Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55, 2104-2110.
49. Gleason DF (1977). The Veteran's Administration Cooperative Urological Research Group: Histological grading and clinical staging of prostate carcinoma. In Tannenbaum M (Ed). Urologic Pathology: The Prostate, Philadelphia, PA: Lea & Febiger, pp. 171-198.